|
INTRODUCTION
As negative trial results edge the HRT market into decline, osteoporosis players have an opportunity to gain market share. Drugs with multiple
indications and convenient dosing regimens will drive market growth. However, best practice promotion and lifecycle management will be as important as
therapeutic advances to establish and maintain competitive advantage.
SCOPE OF THE REPORT
- Breakdown of market composition by IMS and company reported data
- Performance of major drug classes: bisphosphonates, SERMs, calcitonins and HRT, and portfolio analysis of the major players
- Forecasts by class and drug, including impacting events, assumptions, treatment trends, scenario forecasts and strategic opportunities.
- Pricing analysis across four markets and brand analysis of key drugs, including promotional and physician targeting strategy
REPORT HIGHLIGHTS
More negative results in 2003 for HRT have sealed the market's fate and sales are forecast to plummet. Treatment is set to be short-term, low-dose
and less widely prescribed, so it's make or break time for key players, with those in the osteoporosis market well positioned to capitalize on the
losses Additional indications and intermittent dosing of SERMs and pipeline bisphosphonates in osteoporosis will drive sales to dominate therapy and
help to double market value by 2011. However, therapeutic advances must go hand-in-hand with best practice promotion, in terms of launch strategy and
market penetration, to secure commercial success
KEY REASONS TO BUY THIS REPORT
- Assess market, class and drug revenue potential, identify key trends and impacts by using Datamonitor's forecasts of marketed and pipeline
products
- Identify best-practice promotional strategy to end-users in the osteoporosis market
- Predict the impact of key growth drivers on the market, such as intermittent dosing and multiple indications
| 
View Cart
